Skip to main content
SpringerLink
Log in

Influence of Bariatric Surgery on the Use and Pharmacokinetics of Some Major Drug Classes

  • Review
  • Published:
Obesity Surgery Aims and scope Submit manuscript

Abstract

The purpose of this review is to evaluate the influence of bariatric surgery on the use and pharmacokinetics of some frequently used drugs. A PubMed literature search was conducted. Literature was included on influence of bariatric surgery on pharmacoepidemiology and pharmacokinetics. Drug classes to be searched for were antidepressants, antidiabetics, statins, antihypertensive agents, corticosteroids, oral contraceptives, and thyroid drugs. A reduction in the use of medication by patients after bariatric surgery has been reported for various drug classes. Very few studies have been published on the influence of bariatric surgery on the pharmacokinetics of drugs. After bariatric surgery, theoretically, reduced drug absorption may occur. Correct dosing and choosing the right dosage form for drugs used by patients after bariatric surgery are necessary for optimal pharmacotherapy. Therefore, more clinical studies are needed on the influence of bariatric surgery on the pharmacokinetics of major drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–67.

    Article  PubMed  Google Scholar 

  2. Leff DR, Heath D. Surgery for obesity in adulthood. Br Med J. 2009;339:740–6.

    Article  Google Scholar 

  3. Samuel I, Mason EE, Renquist KE, et al. Bariatric surgery trends: An 18-year report from the International Bariatric Surgery Registry. Am J Surg. 2006;192:657–62.

    Article  PubMed  Google Scholar 

  4. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical complications. Obes Rev. 2010;11:41–50.

    Article  PubMed  CAS  Google Scholar 

  5. MacGregor AMC, Boggs L. Drug distribution in obesity and following bariatric surgery: A literature review. Obes Surg. 1996;6:17–27.

    Article  PubMed  Google Scholar 

  6. Malone M. Altered drug disposition in obesity and after bariatric surgery. Nutr Clin Pract. 2003;18:131–5.

    Article  PubMed  Google Scholar 

  7. Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm. 2006;63:1852–57.

    Article  PubMed  Google Scholar 

  8. Segal JB, Clark JM, Shore AD, et al. Prompt reduction in use of medications for comorbid conditions after bariatric surgery. Obes Surg. 2009;19:1646–56.

    Article  PubMed  Google Scholar 

  9. Cunningham JL, Merrell CC, Sarr M, et al. Investigation of antidepressant medication usage after bariatric surgery. Obes Surg. 2012;22:530–5.

    Article  PubMed  Google Scholar 

  10. Voelker M, Foster TG. Nursing challenges in the administration of oral antidepressant medications in gastric bypass patients. J Perianesth Nurs. 2007;22:108–24.

    Article  PubMed  Google Scholar 

  11. Seaman JS, Bowers SP, Dixon P, et al. Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model. Psychosomatics. 2005;46:250–3.

    Article  PubMed  Google Scholar 

  12. Roerig JL, Steffen K, Zimmerman C, et al. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis. 2012;8:62–6.

    Article  PubMed  Google Scholar 

  13. Hamad GG, Helsel JC, Perel JM, et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. 2012;169:256–63.

    Article  PubMed  Google Scholar 

  14. Scheen A-J, De Flines J, De Roover A, et al. Bariatric surgery in patients with type 2 diabetes: Benefits, risks, indications and perspectives. Diabetes Metab. 2009;35:537–43.

    Article  PubMed  CAS  Google Scholar 

  15. Renard E. Bariatric surgery in patients with late-stage type 2 diabetes: Expected beneficial effects on risk ratio and outcomes. Diabetes Metab. 2009;35:564–8.

    Article  PubMed  CAS  Google Scholar 

  16. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and β-cell function in type 2 diabetes. Diabetes Care. 2009;32:514–20.

    Article  PubMed  Google Scholar 

  17. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: Systematic review and meta-analysis. Am J Med. 2009;122:248–56.

    Article  PubMed  Google Scholar 

  18. Dixon JB, Le Roux CW, Rubino F, et al. Bariatric surgery for type 2 diabetes. Lancet. 2012;379:2300–11.

    Article  PubMed  Google Scholar 

  19. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012;308:1122–31.

    Article  PubMed  CAS  Google Scholar 

  20. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en-Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–84.

    PubMed  Google Scholar 

  21. Brancatisano A, Wahlroos S, Matthews S, et al. Gastric banding for the treatment of type 2 diabetes mellitus in morbidly obese. Surg Obes Relat Dis. 2008;4:423–9.

    Article  PubMed  Google Scholar 

  22. Dorman RB, Serrot FJ, Miller CJ, et al. Case-matched outcomes in bariatric surgery for treatment of type 2 diabetes in the morbidly obese patient. Ann Surg. 2012;255:287–93.

    Article  PubMed  Google Scholar 

  23. Pournaras DJ, Aasheim ET, Søvik TT, et al. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg. 2012;99:100–3.

    Article  PubMed  CAS  Google Scholar 

  24. Jurowich C, Thalheimer A, Hartmann D, et al. Improvement of type 2 diabetes mellitus (T2DM) after bariatric surgery—who fails in the early postoperative course? Obes Surg. 2012;22:1521–6.

    Article  PubMed  CAS  Google Scholar 

  25. Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299:316–23.

    Article  PubMed  CAS  Google Scholar 

  26. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. NJEM. 2012;366:1577–85.

    Article  CAS  Google Scholar 

  27. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. NJEM. 2012;366:1567–76.

    Article  CAS  Google Scholar 

  28. Malone M, Alger-Mayer SA. Medication use patterns after gastric bypass surgery for weight management. Ann Pharmacother. 2005;39:637–42.

    Article  PubMed  Google Scholar 

  29. Segato G, Busetto L, De Luca M, et al. Weight loss and changes in use of antidiabetic medication in obese type 2 diabetics after laparoscopic gastric banding. Surg Obes Rel Dis. 2010;6:132–7.

    Article  Google Scholar 

  30. Maciejewski ML, Livinston EH, Kahwati LC, et al. Discontinuation of diabetes and lipid-lowering medications after bariatric surgery at Veterans Affairs medical centers. Surg Obes Rel Dis. 2010;6:601–7.

    Article  Google Scholar 

  31. Nocca D, Guillaume F, Noel P, et al. Impact of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on HbA1c blood level and pharmacological treatment of type 2 diabetes mellitus in severe or morbidly obese patients. Results of a multicenter prospective study at 1 year. Obes Surg. 2011;21:738–43.

    Article  PubMed  Google Scholar 

  32. Narbro K, Ågren G, Jonsson E, et al. Pharmaceutical costs in obese individuals. Comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: The SOS intervention study. Arch Intern Med. 2002;162:2061–9.

    Article  PubMed  Google Scholar 

  33. Potteiger CE, Paragi PR, Inverso NA, et al. Bariatric surgery: Shredding the monetary weight of prescription costs in the managed care arena. Obes Surg. 2004;14:725–30.

    Article  PubMed  Google Scholar 

  34. Nguyen NT, Varela E, Sabio A, et al. Reduction in prescription medication costs after laparoscopic gastric bypass. Am Surg. 2006;72:853–6.

    PubMed  Google Scholar 

  35. Makary MA, Clarke JM, Shore AD, et al. Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery. Arch Surg. 2010;145:726–31.

    Article  PubMed  Google Scholar 

  36. Klein S, Ghosh A, Cremieux PY, et al. Economic impact of the clinical benefits of bariatric surgery in diabetes patients with BMI ≥ 35 kg/m2. Obesity. 2011;19:581–7.

    Article  PubMed  Google Scholar 

  37. Ghiassi S, Morton J, Bellatore N, et al. Short-term medication cost savings for treating hypertension and diabetes after gastric bypass. Surg Obes Relat Dis. 2012;8:269–74.

    Article  PubMed  Google Scholar 

  38. Neovius M, Narbro K, Keating C, et al. Health care use during 20 years following bariatric surgery. JAMA. 2012;308:1132–41.

    Article  PubMed  CAS  Google Scholar 

  39. Padwal RS, Gabr RQ, Sharma AM, et al. Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care. 2011;34:1295–300.

    Article  PubMed  CAS  Google Scholar 

  40. Skottheim IB, Stormark K, Christensen H, et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther. 2009;86:311–8.

    Article  PubMed  CAS  Google Scholar 

  41. Skottheim IB, Jakobsen GS, Stormark K, et al. Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. Clin Pharmacol Ther. 2010;87:699–705.

    Article  PubMed  CAS  Google Scholar 

  42. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol. 2005;19:117–25.

    Article  PubMed  CAS  Google Scholar 

  43. Donadelli SP, Salgado W, Marchini JS, et al. Change in predicted 10-year cardiovascular risk following Roux-en-Y gastric bypass surgery: Who benefits? Obes Surg. 2011;21:569–73.

    Article  PubMed  Google Scholar 

  44. Hodo DM, Waller JL, Martindale RG, et al. Medication use after bariatric surgery in a managed care cohort. Surg Obes Rel Dis. 2008;4:601–7.

    Article  Google Scholar 

  45. Crémieux PY, Ledoux S, Clerici C, et al. The impact of bariatric surgery on comorbidities and medication use among obese patients. Obes Surg. 2010;20:861–70.

    Article  PubMed  Google Scholar 

  46. Wójcicki J, Wojciechowski G, Wójcicki M, et al. Pharmacokinetics of propranolol and atenolol in patients after partial gastric resection: A comparative study. Eur J Clin Pharmacol. 2000;56:75–9.

    Article  PubMed  Google Scholar 

  47. Valdivieso A, Calvo R, Gonzalez JP, et al. Influence of several surgical techniques in peptic ulcer disease on the oral kinetic of a basic drug. Acta Chir Belg. 1993;93:88–91.

    PubMed  CAS  Google Scholar 

  48. Reddy RC, Baptist AP, Fan Z, et al. The effects of bariatric surgery on asthma severity. Obes Surg. 2011;21:200–6.

    Article  PubMed  Google Scholar 

  49. Sikka N, Wegienka G, Havstad S, et al. Respiratory medication prescriptions before and after bariatric surgery. Ann Allergy Asthma Immunol. 2010;104:326–30.

    Article  PubMed  Google Scholar 

  50. Merhi ZO. Impact of bariatric surgery on female reproduction. Fertil Steril. 2009;92:1501–8.

    Article  PubMed  Google Scholar 

  51. Gerrits EG, Ceulemans R, Van Hee R, et al. Contraceptive treatment after biliopancreatic diversion needs consensus. Obes Surg. 2003;13:378–82.

    Article  PubMed  Google Scholar 

  52. Merhi ZO. Challenging oral contraception after weight loss by bariatric surgery. Gynecol Obstet Invest. 2007;64:100–2.

    Article  PubMed  Google Scholar 

  53. Paulen ME, Zapata LB, Cansino C, et al. Contraceptive use among women with a history of bariatric surgery: A systematic review. Contraception. 2010;82:86–94.

    Article  PubMed  Google Scholar 

  54. Raftopoulos Y, Gagné DJ, Papasavas P, et al. Improvement of hypothyroidism after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2004;14:509–13.

    Article  PubMed  Google Scholar 

  55. Fazylov R, Soto E, Cohen S. Laparoscopic Roux-en-Y gastric bypass surgery on morbidly obese patients with hypothyroidism. Obes Surg. 2008;18:644–7.

    Article  PubMed  Google Scholar 

  56. Gniuli D, Leccesi L, Guidone C, et al. Thyroid function and insulin sensitivity before and after bilio-pancreatic diversion. Obes Surg. 2010;20:61–8.

    Article  PubMed  Google Scholar 

  57. Rubio IGS, Galrão AL, Santo MA, et al. Levothyroxine absorption in morbidly obese patients before and after Roux-en-Y gastric bypass (RYGB) surgery. Obes Surg. 2012;22:253–8.

    Article  PubMed  Google Scholar 

  58. Lizer MH, Papageorgeon H, Glembot TM. Nutritional and pharmacologic challenges in the bariatric surgery patient. Obes Surg. 2010;20:1654–9.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy and Clinical Pharmacology, Medisch Centrum Leeuwarden, PO Box 888, 8901 BR, Leeuwarden, The Netherlands

    Jan Peter Yska, Susanne van der Linde, Véronique V. Tapper & Eric N. van Roon

  2. Department of Surgery, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands

    Jan A. Apers, Marloes Emous & Erik R. Totté

  3. Unit of Pharmacotherapy and Pharmaceutical Care, Department of Pharmacy, University of Groningen, Groningen, The Netherlands

    Bob Wilffert

  4. Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

    Bob Wilffert

Authors
  1. Jan Peter Yska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne van der Linde
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Véronique V. Tapper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan A. Apers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marloes Emous
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Erik R. Totté
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bob Wilffert
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eric N. van Roon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Peter Yska.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yska, J.P., van der Linde, S., Tapper, V.V. et al. Influence of Bariatric Surgery on the Use and Pharmacokinetics of Some Major Drug Classes. OBES SURG 23, 819–825 (2013). https://doi.org/10.1007/s11695-013-0882-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11695-013-0882-6

Keywords

Search

Navigation